AACR and American Association for Cancer Research

Selected news for the healthcare topic - AACR, and the healthcare topic - American Association for Cancer Research We have 775 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
4/15/2021 AACR 2021: Research explains reasons behind variability in tumor response to different treatments Able to obtain millions of data point from individual cells, single-cell analysis achieves unprecedented scale and resolution, heard attendees at a joint symposium run by the American Association for Cancer Research (AACR) and the Chinese Society of Clinical Oncology (CSCO) this week: Changing the Landscape of Cancer Research ‚Aa.Speakers participating in that AACR 2021 event said such technologies are transforming the understanding of cancer biology, allowing researchers to ...
4/15/2021 Prostate cancer specialist honored for translational, clinical research American Association for Cancer Research presented the AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research to Nima Sharifi, MD .The award is presented to a cancer researcher who has conducted highly meritorious translational and clinical cancer research and who is aged 50 years or younger at the time of award presentation. Sharifi is director of Center for Genitourinary Malignancies Research at Lerner Research Institute ...
4/15/2021 Mutant KRAS and p53 Cooperate to Drive Pancreatic Cancer Metastasis ... American Association for Cancer Research (AACR) Annual Meeting 2021 by Michael Kim, M.D., assistant professor of Surgical Oncology and Genetics. Read more . . . Related Stories ...
4/15/2021 MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021 Early phase clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with RET fusion-positive cancers, high-grade (HGG) and low-grade glioma (LGG) and ovarian cancer. The results, presented today at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, showcase the researchers‚Ao ongoing efforts to advance clinical studies and expand potential indications of approved drugs ...
4/15/2021 Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials ... American Association for Cancer Research (AACR) annual meeting to be held 9-14 April, 2021. With this announcement, the company‚Aos AI technologies and drug-hunting expertise are now responsible for the first two AI-designed drugs to enter Phase I testing, following on from Exscientia‚Aos previous announcement in 2020 . Andrew Hopkins, CEO of Exscientia said, ‚AuImmuno-oncology medicines are bringing benefit to a range of cancer patients. Our selective ...
4/15/2021 AACR: Ovarian Cancer Patients at Higher Risk for Mental Illness FDA Alerts AACR: Ovarian Cancer Patients at Higher Risk for Mental Illness Women diagnosed with ovarian cancer are more than three times more likely to be diagnosed with mental illnesses, such as anxiety, depression, and adjustment disorder, compared with the general public, according to a study presented during Week 1 of the annual meeting of the American Association for Cancer Research, held virtually from April 10 to 15.Siqi Hu ...
4/14/2021 PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases | Financial Buzz PsiOxus Therapeutics, Ltd . (PsiOxus), a clinical stage oncology company ‚Aare-programming ‚Aathe tumor microenvironment to overcome the central challenge of resistance to therapy, and bluebird bio, Inc. (Nasdaq: BLUE) presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2021. The study, ‚AuT-SIGn cancer gene therapy and anti-EGFR CAR-T cells synergize in combination therapy to clear A549 lung tumor xenografts‚Au, assessed anti-tumor ...
4/14/2021 AACR 2021: Addition of Copanlisib Improves Lymphoma Outcomes Physicians Weekly AACR 2021: Addition of Copanlisib Improves Lymphoma OutcomesApr 14, 2021 Disease progression slowed with copanlisib/rituximab comboThe combination of copanlisib plus rituximab appears to significantly increase the median time to progression of relapsed indolent non-Hodgkin‚Aos lymphoma when compared to treatment with rituximab alone ‚Ai the current standard-of-care, researchers reported at the 2021 virtual meeting of the American Association for Cancer Research.Patients treated with ...
4/13/2021 Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021 | Markets Insider Business Insider ... American Association for Cancer Research (AACR) Annual Meeting 2021.ORIENT-3 is a randomized, open-label, Phase 3 clinical trial evaluating TYVYT® (sintilimab injection) versus docetaxel as a second-line treatment for advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). A total of 290 patients whose cancer had progressed following first-line treatment with platinum-based chemotherapy were enrolled. Based on the primary analysis population (280 patients ...
4/13/2021 Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021 | Markets Insider Business Insider ... American Association for Cancer Research (AACR) Annual Meeting 2021.ORIENT-3 is a randomized, open-label, Phase 3 clinical trial evaluating TYVYT® (sintilimab injection) versus docetaxel as a second-line treatment for advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). A total of 290 patients whose cancer had progressed following first-line treatment with platinum-based chemotherapy were enrolled. Based on the primary analysis population (280 patients ...
4/13/2021 Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021 SAN FRANCISCO and SUZHOU, China, Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced with Eli Lilly and Company ("Lilly", NYSE: LLY) that the results of the Phase 3 ORIENT-3 study were released today in an oral presentation at the American Association for Cancer Research (AACR) Annual ...
4/13/2021 Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021 ... American Association for Cancer Research (AACR) Annual Meeting 2021. ORIENT-3 is a randomized, open-label, Phase 3 clinical trial evaluating TYVYT® (sintilimab injection) versus docetaxel as a second-line treatment for advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). A total of 290 patients whose cancer had progressed following first-line treatment with platinum-based chemotherapy were enrolled. Based on the primary analysis population (280 patients ...
4/12/2021 AACR: In Phase 1 Study, Novel Agent Appears to Improve Pediatric Glioma Survival Physicians Weekly AACR: In Phase 1 Study, Novel Agent Appears to Improve Pediatric Glioma SurvivalApr 12, 2021 Cancer-fighting virus has few adverse effectsA genetically-engineered oncolytic herpes simplex virus administered into the brain, G207 ... of Alabama at Birmingham.At the virtual meeting of the American Association for Cancer Research , he reported that 11 of 12 pediatric patients showed radiological, neuropathological or clinical response to therapy, and that four patients ...
4/12/2021 Flagship Biosciences and Leap Therapeutics Announce Partnership and Approach Using RNAscope and Image Analysis for Patient Enrollment PR Newswire WESTMINSTER, Colo. and CAMBRIDGE, Mass. , April 12, Flagship Biosciences , the leader in data-centric pathology and tissue analysis, and Leap Therapeutics (Nasdaq: LPTX ), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced a partnership to use a clinically validated tumor expression assay utilizing RNAscope ® and tissue image analysis. In a poster shared this week at the American Association for Cancer Research (AACR) Annual Meeting 2021 ...
4/12/2021 AACR: OncoMyx's engineered rabbit pox virus shows promise in lung cancer model | FierceBiotech FierceBiotech ... American Association for Cancer Research (AACR) virtual annual meeting. OncoMyx believes the data build on a growing body of evidence that supports the development of its oncolytic virus, which its scientsts are engineering to carry therapeutic proteins that directly eliminate cancer cells while simultaneously stimulating an anti-tumor immune response. The virus at the core of OncoMyx‚Aos therapy doesn‚Aot cause disease in humans but can infect cancer cells ...
4/12/2021 AACR: Healthy Lifestyle May Counter High Genetic Risk for Lethal Prostate Cancer Physicians Weekly AACR: Healthy Lifestyle May Counter High Genetic Risk for Lethal Prostate CancerApr 12, 2021MONDAY, April 12, 2021 (HealthDay News) ‚Ai Genetic factors are associated with an increased risk for overall and lethal prostate ... presented during Week 1 of the annual meeting of the American Association for Cancer Research, held virtually from April 10 to 15.Anna Plym, Ph.D., from Brigham and Women‚Aos Hospital in Boston, and colleagues ...
4/12/2021 AACR: Personalized Vaccine for Cancer Tolerated, Feasible Physicians Weekly AACR: Personalized Vaccine for Cancer Tolerated, Feasible A personalized vaccine can be synthesized and is feasible for administration to patients with cancer, according to a study presented during Week 1 of the annual meeting of the American Association for Cancer Research, held virtually from April 10 to 15.Thomas Urban Marron, M.D., Ph.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues developed a ...
4/12/2021 AACR 2021: Research points to ways to fight cachexia's bite | 2021-04-12 | BioWorld BioWorld Cachexia, Teresa Zimmers told the audience at the Annual Meeting of the American Association for Cancer Research (AACR), is "woefully understudied for the outsized impact it has on cancer patients." The condition, which is currently defined as weight loss and muscle wasting, is the direct cause of death in an estimated 25% to 30% of cancer patients. But it is the main subject of only 0.1% of research papers and ...
4/12/2021 The Ridgway Record ... American Association for Cancer Research (AACR) Annual Meeting 2021.ORIENT-3 is a randomized, open-label, Phase 3 clinical trial evaluating TYVYT® (sintilimab injection) versus docetaxel as a second-line treatment for advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). A total of 290 patients whose cancer had progressed following first-line treatment with platinum-based chemotherapy were enrolled. Based on the primary analysis population (280 patients ...
4/12/2021 SAN FRANCISCO and SUZHOU, China, April 12, 2021 /P ... American Association for Cancer Research (AACR) Annual Meeting 2021.ORIENT-3 is a randomized, open-label, Phase 3 clinical trial evaluating TYVYT® (sintilimab injection) versus docetaxel as a second-line treatment for advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). A total of 290 patients whose cancer had progressed following first-line treatment with platinum-based chemotherapy were enrolled. Based on the primary analysis population (280 patients ...
4/12/2021 A Win for Nivolumab as Preoperative Therapy for Lung Cancer ... American Association for Cancer Research (AACR) virtual meeting." CheckMate 816 showed a statistically significant improvement in pCR," said Forde. "This benefit was consistent across disease stages, histology, TMB (tumor mutational burden) and PD-L1 expression. The study continues to mature for the event-free survival (EFS) primary endpoint.""The addition of neoadjuvant nivolumab to chemo maintained a tolerable safety profile and did not impede the feasibility of surgery," he added ...
4/11/2021 New Clinical Responses for AGEN1181 Presented at AACR New Clinical Responses for AGEN1181 Presented at AACR 7 objective responses observed to date in multiple tumor types New responses reported in patients with melanoma and ovarian cancer Benefit seen in patients typically unresponsive to ... AGEN1181, its next-generation anti-CTLA-4 antibody, at the American Association for Cancer Research (AACR) Annual Meeting from April 10 ‚Ai 15, 2021. ‚AuThe preclinical and translational data in conjunction with our updated clinical ...
4/11/2021 New Clinical Responses for AGEN1181 Presented at AACR New Clinical Responses for AGEN1181 Presented at AACR 7 objective responses observed to date in multiple tumor types New responses reported in patients with melanoma and ovarian cancer Benefit seen in patients typically unresponsive to ... AGEN1181, its next-generation anti-CTLA-4 antibody, at the American Association for Cancer Research (AACR) Annual Meeting from April 10 ‚Ai 15, 2021. ‚AuThe preclinical and translational data in conjunction with our updated clinical ...
4/11/2021 Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting Yahoo News ... American Association for Cancer Research (AACR) Annual Meeting, held virtually April 10-15, 2021 ."We are excited to broaden the body of evidence for Retevmo in RET fusion-positive cancers beyond lung and thyroid tumors," said David Hyman , M.D., chief medical officer, oncology at Lilly. "These encouraging outcomes, including in difficult-to-treat GI malignancies, support a growing body of evidence that RET fusions are potentially actionable in a wide range ...
4/11/2021 BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021 Yahoo News ... American Association for Cancer Research (AACR) Annual Meeting 2021. Data presented at the meeting were from two cohorts of a Phase 1b trial (NCT03666143), in patients with unresectable or metastatic melanoma who were refractory or resistant to PD-1/L1 inhibitors and in patients with advanced platinum-resistant ovarian cancer (PROC).BeiGene has an exclusive collaboration and license agreement with Mirati for the development, manufacturing and commercialization of sitravatinib in ...